This strategy would not only target platelets but also activated Treg and GARP+ tumor cells, leading to the modulation of the inhibitory tumor microenvironment with the overall aim to overcome cancer’s resistance to immunotherapy through this combinatorial approach. This evidence concerns the gene LRRC32 and cancer.